Denali Therapeutics
$17.799876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$17.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.31 (-1.71%) Today
$0.00 (0.00%) As of 4:30 PM EDT after-hours
Why Robinhood?
You can buy or sell DNLI and other stocks, options, ETFs, and crypto commission-free!
About DNLI
Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Read More Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Employees
179
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.71B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
251.51K
High Today
$18.52
Low Today
$17.70
Open Price
$18.00
Volume
252.21K
52 Week High
$28.87
52 Week Low
$13.78
Collections
Price Paid on Robinhood
8% Lower
Right Now
52 Week Low
$12.32
Average Price Paid
$19.26
52 Week High
$28.87
Analyst Ratings
50%
of 8 ratings
Buy
50%
Hold
50%
Sell
0%
DNLI Earnings
-$0.61
-$0.14
$0.32
$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected Nov 7, After Hours